新兴疗法用于治疗全身性硬化症
Jörg H W Distler1,2, Masataka Kuwana3, Shervin Assassi4
1Department of Rheumatology, University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany. joerg.distler@med.uni-duesseldorf.de.
Nature reviews. Rheumatology
|September 8, 2025
概括
系统性硬化症 (SSc) 是一种严重的自身免疫性疾病,导致纤维化和器官衰竭. 目前正在进行的临床试验为新疗法提供了希望,以减缓疾病进展并改善患者的治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 纤维化研究 纤维化研究
背景情况:
- 系统性硬化症 (SSc) 是一种复杂的自身免疫性疾病,其特征是纤维化,血管和自身免疫机制的协同作用.
- SSc导致显著的发病率和死亡率,主要是由于渐进的纤维组织重塑和器官衰竭.
- 尽管最近有治疗方面的进步,但患者的治疗结果仍然很差,死亡率为50%,这凸显了急需有效治疗的迫切需要.
研究的目的:
- 突出新型和有效治疗系统性硬化症的关键需求.
- 要强调SSc中的活跃药物开发格局,临床试验中的许多药物.
- 通过新的治疗方法的潜力,传达改善患者治疗结果的希望,以阻止纤维化进展.
主要方法:
- 审查目前对SSc病原学的理解.
- 对SSc药物开发管道的分析.
- 对SSc疗法的正在进行和即将进行的临床试验的审查.
主要成果:
- SSc病变发生涉及纤维化,血管和自身免疫因素的复杂相互作用.
- 尽管有现有的治疗方法,但死亡率仍然很高,这表明存在大量未满足的医疗需求.
- 一系列针对各种机制的新药正在临床试验中进行研究.
结论:
- 系统性硬化症仍然是死亡率高的疾病,需要创新的治疗策略.
- 活跃的药物开发和许多正在进行的临床试验为SSc治疗的未来提供了重大前景.
- 这些试验旨在减缓或停止纤维化进展,可能改变SSc患者的结果.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
441
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441
iPS Cell Differentiation
3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
495
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
495
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
466
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
466
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K


